Close Menu

NEW YORK – Nijmegen, Netherlands-based Enzyre said on Thursday that it has entered into a research collaboration agreement with Takeda Pharmaceutical to develop a diagnostic test that will enable hemophilia patients to determine their coagulation status at home.

Under the terms of the agreement, Takeda will provide funding to Enzyre to tailor its technology to enable automatic determination of the coagulation status of hemophilic patients and transfer the test results to the patients' treating physicians through a mobile phone app.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.